Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) has entered a significant research partnership with US biotechnology company Nabla Bio to enhance the use of AI in drug delivery [1][2] - The partnership builds on a previous collaboration initiated in 2022, where Nabla will utilize its AI platform, the Joint Atomic Model (JAM), to develop protein-based treatments for Takeda's early-stage pipeline [2] - Takeda will make an upfront payment in double-digit millions to Nabla, with potential success-based payments exceeding $1 billion [3] Company Overview - Takeda Pharmaceutical Company Limited is a Japanese biotech firm focused on the research, development, and sale of pharmaceuticals, particularly in areas such as gastrointestinal, rare, immune, cancer, and neuropsychiatric diseases [4]